These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9617437)

  • 21. Presence of organ‑specific antibodies in patients with systemic sclerosis.
    Wielosz E; Majdan M; Koszarny A; Dryglewska M; Tabarkiewicz J
    Pol Arch Med Wewn; 2016 Oct; 126(11):862-869. PubMed ID: 27906879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.
    Goel N; Ulrich DT; St Clair EW; Fleming JA; Lynch DH; Seldin MF
    Arthritis Rheum; 1995 Dec; 38(12):1738-43. PubMed ID: 8849345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
    Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
    Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Assessment of serum IgG activity correlation against cyclic citrullinated peptide antibodies, topoisomerase I and centromere proteins in Mexican patients with progressive systemic sclerosis].
    Rocha-Muñoz AD; González-López L; Peguero-Gómez R; Aguilar-Chávez EA; Villa-Manzano AI; Corona-Sánchez E; Galván-Méndez S; Presiado-Sánchez C; Vázquez-Jiménez JC; Riebeling C; Salazar-Páramo M; Gámez-Nava JI; Nava A
    Rev Alerg Mex; 2009; 56(4):103-7. PubMed ID: 19768971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
    Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
    J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
    Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
    Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
    Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased serum soluble CD40 levels in patients with systemic sclerosis.
    Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies.
    Sato S; Ihn H; Soma Y; Shimozuma M; Shishiba T; Takehara K
    J Rheumatol; 1993 Nov; 20(11):1961-3. PubMed ID: 8308786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum level of circulating syndecan-1: A possible association with proliferative vasculopathy in systemic sclerosis.
    Wu CY; Asano Y; Taniguchi T; Sato S; Yu HS
    J Dermatol; 2016 Jan; 43(1):63-6. PubMed ID: 26076711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apoptosis and peripheral blood lymphocyte depletion in coeliac disease.
    Di Sabatino A; D'Alò S; Millimaggi D; Ciccocioppo R; Parroni R; Sciarra G; Cifone MG; Corazza GR
    Immunology; 2001 Aug; 103(4):435-40. PubMed ID: 11529933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis.
    Toyama T; Asano Y; Takahashi T; Aozasa N; Akamata K; Noda S; Taniguchi T; Ichimura Y; Sumida H; Tamaki Z; Masui Y; Tada Y; Sugaya M; Sato S; Kadono T
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):337-44. PubMed ID: 22211766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
    Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S
    Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease.
    Fujimoto M; Hasegawa M; Hamaguchi Y; Komura K; Matsushita T; Yanaba K; Kodera M; Takehara K; Sato S
    Dermatology; 2006; 213(2):88-92. PubMed ID: 16902284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.
    Knipping E; Krammer PH; Onel KB; Lehman TJ; Mysler E; Elkon KB
    Arthritis Rheum; 1995 Dec; 38(12):1735-7. PubMed ID: 8849344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.
    Ateş A; Kinikli G; Turgay M; Duman M
    Clin Rheumatol; 2004 Oct; 23(5):421-5. PubMed ID: 15459814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.